UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

Healthcare Professionals

Patients

Investors

31 Redefining Hidradenitis Suppurativa (HS) Care Through Community and Collaboration

Read More Share:

Oct

31 BIMZELX® (bimekizumab-bkzx) Data in Hidradenitis Suppurativa Showed Improvements in Pain and Resolution of Draining Tunnels Sustained to Three Years

Read More Share:

Oct

29 UCB opens applications for 2026 UCB Myasthenia Gravis Scholarship™

Read More Share:

Oct

29 UCB to unveil new data for RYSTIGGO® (rozanolixizumab-noli) and ZILBRYSQ®(zilucoplan) for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific Session

Read More Share:

Oct

27 Generalized myasthenia gravis management with shared decision-making

Read More Share:

Oct

25 BIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis

Read More Share:

Oct

23 Multidisciplinary Collaboration as the Future of Patient-Centered Care

Read More Share:

Oct

14 Innovative Collaborations: Enhancing Epilepsy Care through UCB and Morehouse's Community-Based Approach

Read More Share:

Oct

14 Final analysis of open-label extension (OLE) study of FINTEPLA® (fenfluramine) in Lennox-Gastaut syndrome published in Epilepsy & Behavior

Read More Share:

Oct

13 Results published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d)

Read More Share:

Categories

Archives

Oct

31

Redefining Hidradenitis Suppurativa (HS) Care Through Community and Collaboration

Oct

31

BIMZELX® (bimekizumab-bkzx) Data in Hidradenitis Suppurativa Showed Improvements in Pain and Resolution of Draining Tunnels Sustained to Three Years

Oct

29

UCB opens applications for 2026 UCB Myasthenia Gravis Scholarship™

Oct

29

UCB to unveil new data for RYSTIGGO® (rozanolixizumab-noli) and ZILBRYSQ®(zilucoplan) for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific Session

Oct

27

Generalized myasthenia gravis management with shared decision-making

Oct

25

BIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis

Oct

23

Multidisciplinary Collaboration as the Future of Patient-Centered Care

Oct

14

Innovative Collaborations: Enhancing Epilepsy Care through UCB and Morehouse's Community-Based Approach

Oct

14

Final analysis of open-label extension (OLE) study of FINTEPLA® (fenfluramine) in Lennox-Gastaut syndrome published in Epilepsy & Behavior

Oct

13

Results published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d)

Choose Country

UCB in the U.S.

Patients

Innovation

Disease Areas

Sustainability

Newsroom

Contact

Categories

Archives

Oct

31

Redefining Hidradenitis Suppurativa (HS) Care Through Community and Collaboration

Oct

31

BIMZELX® (bimekizumab-bkzx) Data in Hidradenitis Suppurativa Showed Improvements in Pain and Resolution of Draining Tunnels Sustained to Three Years

Oct

29

UCB opens applications for 2026 UCB Myasthenia Gravis Scholarship™

Oct

29

UCB to unveil new data for RYSTIGGO® (rozanolixizumab-noli) and ZILBRYSQ®(zilucoplan) for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific Session

Oct

27

Generalized myasthenia gravis management with shared decision-making

Oct

25

BIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis

Oct

23

Multidisciplinary Collaboration as the Future of Patient-Centered Care

Oct

14

Innovative Collaborations: Enhancing Epilepsy Care through UCB and Morehouse's Community-Based Approach

Oct

14

Final analysis of open-label extension (OLE) study of FINTEPLA® (fenfluramine) in Lennox-Gastaut syndrome published in Epilepsy & Behavior

Oct

13

Results published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d)

Choose Country

UCB in the U.S.

Patients

Innovation

UCB Worldwide

Disease Areas

Sustainability

Newsroom

Contact